Showing results (231-240 of 246) with videos related to

Sort By:
Pageof 25
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 17, 2018
Correlation of extent of ALK FISH positivity and crizotinib efficacy in three prospective studies of ALK-positive patients with non-small-cell lung cancerJ-C Soria, S N Ho, M Varella-Garcia, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 2019
Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOSY-L Wu, D Planchard, S Lu, et al.
British Journal of Cancer|January 20, 2017
A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutationsJ J Yang, Q Zhou, H H Yan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 28, 2023
Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLCT S K Mok, G Lopes, B C Cho, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 5, 2014
Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR (CTONG0806): a multicenter randomized trialQ Zhou, Y Cheng, J-J Yang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 25, 2015
First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE studyY-L Wu, C Zhou, C-K Liam, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 8, 2016
Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trialsJ C-H Yang, L V Sequist, C Zhou, et al.
ESMO Open|November 21, 2023
Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trialH Borghaei, K J O'Byrne, L Paz-Ares, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 5, 2015
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)C Zhou, Y L Wu, G Chen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 5, 2013
Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)G Chen, J Feng, C Zhou, et al.
Pageof 25